The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Official Title: A Phase 1 Study of BMS-986416 Alone and in Combination With Nivolumab in Select Solid Tumors
Study ID: NCT04943900
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, drug effects, drug levels and preliminary antitumor activity of BMS-986416 when administered alone and in combination with Nivolumab in participants with select advanced solid tumors.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Local Institution - 0006, Atlanta, Georgia, United States
Local Institution - 0005, Baltimore, Maryland, United States
Local Institution - 0002, Hackensack, New Jersey, United States
Local Institution - 0013, Cleveland, Ohio, United States
Local Institution - 0003, Pittsburgh, Pennsylvania, United States
Local Institution - 0004, Houston, Texas, United States
Local Institution - 0021, Ciudad Aut贸noma de Buenos Aires, Buenos Aires, Argentina
Local Institution - 0027, ABB, Ciudad Aut贸noma De Buenos Aires, Argentina
Local Institution - 0022, Caba, Ciudad Aut贸noma De Buenos Aires, Argentina
Local Institution - 0043, Edegem, Antwerpen, Belgium
Local Institution - 0016, Gent, Oost-Vlaanderen, Belgium
Local Institution - 0009, Edmonton, Alberta, Canada
Local Institution - 0008, Toronto, Ontario, Canada
Local Institution - 0001, Montr茅al, Quebec, Canada
Local Institution - 0025, Santiago, Regi贸n Metropolitana De Santiago, Chile
Local Institution - 0026, Santiago, Regi贸n Metropolitana De Santiago, Chile
Local Institution - 0024, Santiago, Regi贸n Metropolitana De Santiago, Chile
Local Institution - 0010, Chuo-ku, Tokyo, Japan
Local Institution - 0020, Maastricht, Limburg, Netherlands
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR